The development of monoclonal antibody therapies targeting specific components of the
pathways relevant to asthma pathophysiology has revolutionized treatment of severe …

Remission has been included as the treatment goal in asthma in several national
guidelines, reflecting the paradigm shift in asthma, from short-term symptom control to long …

Background Novel biologic therapies have revolutionised the management of severe
asthma with more ambitious treatment aims. Here we analyse the definition of clinical …

Introduction Clinical remission (CliR) achievement has been recognized as a new potential
outcome in severe asthma. Nevertheless, we still lack a detailed profile of what features …

Until 2023, guidelines focused on asthma control as the primary goal of asthma treatment, 1
with the step-wise addition of drugs until the best possible disease control was achieved …

Background: Benralizumab has been shown to restore good control of severe eosinophilic
asthma (SEA). Robust data on benralizumab effectiveness over periods longer than 2 years …

Rationale: There is no consensus on criteria to include in an asthma remission definition in
real-life. Factors associated with achieving remission post-biologic-initiation remain poorly …

Background To date, studies investigating the association between pre-biologic biomarker
levels and post-biologic outcomes have been limited to single biomarkers and assessment …

Abstract Purpose of Review The development of biological therapies for type 2 inflammatory
diseases raises the possibility of addressing remission in those dis-immune conditions. No …

Severe asthma is associated with an increased risk for exacerbations, reduced lung
function, fixed airflow obstruction, and substantial morbidity and mortality. The concept of …